罗氟司特纳入医保了吗？

As a new drug for the treatment of chronic obstructive pulmonary disease (COPD), roflumilast is an inhibitor called phosphodiesterase-4 (PDE-4). It is used to treat cough and mucus excess in patients with severe chronic obstructive pulmonary disease (COPD) accompanied by bronchitis. Roflumilast is not used to treat primary emphysema and other types of chronic obstructive pulmonary disease (COPD). Roflumilast can improve mucociliary clearance by increasing the activity of the cystic fibrosis transmembrane transport regulator in bronchial epithelium. In addition, roflumilast can inhibit centrocyte elastase and MMP-9 levels, thereby correcting the imbalance between proteases and anti-proteases in patients with chronic obstructive pulmonary disease COPD, inhibiting the chemotaxis and proliferation of fibroblasts, thereby reversing airway remodeling and improving lung function.

In vitro experiments and animal model tests have shown that roflumilast tablets have extensive anti-inflammatory effects. In vitro, roflumilast N-oxide can affect many cell types, including neutrophils, monocytes/macrophages, CD4+ and CD8+ T cells, endothelial cells, epithelial cells, smooth muscle cells, and fibroblasts. By affecting these cells, roflumilast tablets act on multiple links in the pathogenesis of chronic obstructive pulmonary disease COPD.

Is Roflumilast included in medical insurance? Currently, roflumilast is not marketed in China and is not eligible for medical insurance. It is understood that the current cost-effective roflumilast film tablets are 500μg*90 tablets and sell for about $2,850 per box. The price is not fixed due to factors such as exchange rate fluctuations. If patients want to know the specific price information of this drug, or want to purchase cost-effective roflumilast overseas, they can consult with domestic reliable overseas medical service companies (such as Medical Companion Travel).

  Treatment with roflumilast may result in psychiatric events including suicidal behavior: Advise patients, their caregivers, and families to be alert to the emergence or worsening of insomnia, anxiety, depression, suicidal thoughts or other mood changes, and to contact their healthcare provider if such changes occur. Carefully weigh the risks and benefits of treatment with roflumilast in patients with a history of depression and/or suicidal thoughts or behaviors.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.